Scarica l'app Stockscreener
137.34
0.09%
0.13
Dopo l'orario di chiusura:
136.38
-0.96
-0.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead to buy Ouro Medicines for up to $2.2 billion By Investing.com - Investing.com India
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - The Manila Times
Gilead Sciences to acquire Ouro Medicines in push for autoimmune disease therapies - Traders Union
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal - Reuters
Gilead to acquire Ouro Medicines for up to $2.18 billion By Investing.com - Investing.com India
Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases - TradingView
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases - Yahoo Finance
Gilead Near Deal to Buy Ouro Medicines for Autoimmune Drugs - Bloomberg.com
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - Stocktwits
Gilead Sciences (GILD) Nears $2 Billion Acquisition of Ouro Medi - GuruFocus
Gilead (GILD) Edges Toward $2 Billion Acquisition of Ouro Medici - GuruFocus
Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports By Reuters - Investing.com
Gilead Sciences nears $2 billion Ouro Medicines acquisition - Investing.com Australia
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines - Financial Times
Gilead boss' compensation jumped 20% last year to $28.4 million - The Business Journals
Weekly Recap: Should I set a stop loss on Gilead Sciences Inc2026 WrapUp & Verified Entry Point Signals - baoquankhu1.vn
Gilead Sciences to Buy Arcellx in $7.8B Deal to Strengthen Cell Therapy Portfolio - The Healthcare Technology Report.
Stock Recap: What is the next catalyst for Gilead Sciences Inc2026 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
GILD.SW Gilead Sciences SIX up 70.33% pre-market 23 Mar 2026: valuation risk - Meyka
Arcellx earnings on deck ahead of Gilead acquisition close - Investing.com
Nordea Investment Management AB Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
New England Research & Management Inc. Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
IAM Advisory LLC Takes $1.27 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
BCGM Wealth Management LLC Invests in Gilead Sciences - National Today
BCGM Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Here is what to know beyond why Gilead Sciences, Inc. (GILD) is a trending stock - MSN
Former Gilead Sciences GC To Earn Over $2.5M Severance - Law360
Form DEF 14A GILEAD SCIENCES For: 20 March - Investing.com
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Gilead Ends Obeldesivir Filovirus Prophylaxis Trial: What It Means for GILD Investors - TipRanks
Gilead could potentially end HIV. But will it be able to? - Pharma Voice
Groupama Asset Managment Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Confluence Investment Management LLC Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Anderson Hoagland & Co. Purchases New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
AIA Group Ltd Increases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance
CIBC Bancorp USA Inc. Invests $24.42 Million in Gilead Sciences - National Today
Gilead Sciences, Inc. $GILD Shares Bought by Swiss Life Asset Management Ltd - MarketBeat
Investment Research Partners LLC Takes $928,000 Position in Gilead Sciences, Inc. $GILD - MarketBeat
CIBC Bancorp USA Inc. Makes New $24.42 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Coldstream Capital Management Inc. Acquires 8,807 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
A Look At Gilead Sciences (GILD) Valuation As Recent Returns Send Mixed Signals - Yahoo Finance
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Ciara Is Bringing Back the Pop Culture PSA (Exclusive) - Cosmopolitan
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Gilead Sciences initiates challenging study for aggressive breast cancer form - Traders Union
Antiretroviral Therapy Market Critical Analysis with Expert Opinion| Gilead Sciences, Viatris, AbbVie - openPR.com
Gilead Sciences Inc Stock (GILD) Moved Down by 3.37% on Mar 18: Facts Behind the Movement - TradingKey
Gilead Sciences Stock Performance vs. Business Health Analysis 2026News and Statistics - IndexBox
Is trending stock Gilead Sciences, Inc. (GILD) a buy now? - MSN
Danske Bank A S Takes $133.05 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Captrust Financial Advisors Has $211.80 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Achmea Investment Management B.V. - MarketBeat
Gilead Sciences CFO Dickinson sells $432k in stock - Investing.com
Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares - MarketBeat
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead (GILD) executive sells 3,000 shares in planned trade - Stock Titan
Gilead Sciences (NASDAQ:GILD) CFO Sells $432,690.00 in Stock - MarketBeat
Planned sale: Gilead (NASDAQ: GILD) CFO trims holdings - Stock Titan
Manta Cares and Gilead Sciences Announce Collaboration to Support Patients Navigating Metastatic Breast and Lung Cancer - Femtech Insider
Gilead Sciences ASCENT-04 regimen gains Category 1 status in updated NCCN guidelines - Traders Union
Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast Cancer - PRWeb
Cantor Fitzgerald reiterates Gilead stock rating on Yeztugo sales - Investing.com
National Bank of Canada FI Has $161.14 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Conference: 6-Month HIV Regimens, 12-Month PrEP, Livdelzi Expansion, Oncology Push - Yahoo Finance
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth - MarketBeat
Fort Point Capital Partners LLC Sells 8,153 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bank of Nova Scotia Reduces Gilead Sciences Stake - National Today
CSM Advisors LLC Sells 42,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bank of Nova Scotia Sells 319,843 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
Johanna Mercier sells 28,000 shares at GILD (NASDAQ: GILD) — Form 144 notice - Stock Titan
Gotham Asset Management Increases Gilead Sciences Stake - National Today
Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest Down 15.7% in February - MarketBeat
0.79%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):